Healthcare Innovation

Orlando, Fla. – September 24, 2026 -- Oracle unveiled Oracle Health Oncology EHR, a new ambulatory electronic health record system purpose-built for cancer care, combining oncology-specific workflows with AI-driven clinical intelligence at the Oracle Health and Life Sciences Summit.

Oracle targets fragmented oncology data with unified patient timelines

The platform is designed to consolidate cancer diagnoses, chemotherapy regimens, laboratory and imaging results, medications, referrals, and insurance requirements into a single chronological record spanning inpatient and outpatient settings. Oracle states that fragmented information currently forces clinicians to spend time reassembling patient context while patients repeatedly recount their medical history across care settings.

San Diego – September 24, 2026 -- Werfen has secured U.S. FDA 510(k) clearance and a CE Mark under the EU's IVDR for its Aptiva Antiphospholipid Syndrome (APS) IgA Reagent, completing a three-isotype APS testing portfolio on its Aptiva platform.

Aptiva now covers all three APS antibody isotypes for global laboratories

The clearance means Aptiva offers IgA, IgG, and IgM testing for both anti-cardiolipin (aCL) and anti-beta 2 glycoprotein 1 (aβ2GP1) antibodies, giving laboratories a full antibody profile for antiphospholipid syndrome, an autoimmune disease linked to thrombotic events and pregnancy complications that is often difficult to diagnose due to overlapping clinical symptoms.

Toronto – September 23, 2026 -- The Princess Margaret Cancer Foundation has secured a $100 million gift from an anonymous donor, the largest single donation in the foundation's history and the largest cancer-related gift ever recorded in Canada.

Foundation launches $2.5 billion campaign to fund cancer breakthroughs

The gift anchors the launch of "Carry The Fire," a $2.5 billion fundraising campaign aimed at accelerating cancer research, treatment and care at Princess Margaret Cancer Centre. The donation, tied to the donor's personal experience with cancer, will be directed toward the Centre's highest-priority needs across research, education and patient care, giving administrators flexibility to fund breakthroughs as they emerge.

San Francisco – September 22, 2026 -- Architecture firm NBBJ has partnered with Stanford physician and health economist Dr. Kevin Schulman to redesign hospital campuses for an era of AI-driven care, as health systems commit billions of dollars to facilities meant to operate for decades under uncertain technology trajectories.

Hospitals face multibillion-dollar bets on unpredictable care models

Health systems are currently planning large-scale campuses even as AI, automation and distributed care delivery make it difficult to forecast how medicine will be practiced by the time those buildings open. The partnership targets a specific gap: making long-term real estate investments flexible enough to adapt to care models that do not yet exist.

NEW YORK – September 22, 2026 -- Amigo, a platform for deploying clinical AI, has rebranded as Concurrence, marking an expansion beyond its original scope into unified data infrastructure for health systems, biopharma companies, and public health organizations. The company says its platform has already driven over 10 million patient interactions.

Concurrence builds a unified data foundation called the Health World Model

The Health World Model consolidates institutional data into a single foundation that supplies full patient context to both AI systems and clinicians. AI-powered workflows built on top of this foundation are deployed across the care journey, covering patient intake, medication management, and clinical decision support, capturing patient interactions at what the company describes as an atomic level of detail.

Taipei – September 20, 2026 -- The 2026 Tang Prize Award Ceremony convened in Taipei on September 18, honoring six laureates across four categories including three scientists whose work led to FDA-approved CAR T-cell cancer therapies now used worldwide.

Three biopharmaceutical laureates trace a four-decade path from lab discovery to approved cancer drugs

Dr. Steven A. Rosenberg, who joined remotely, cited his team's work four decades ago showing that tumor-infiltrating lymphocytes (TILs) taken from patients' own tumors could drive cancer regression, establishing the concept of a patient's lymphocytes as a 'living drug.' That research laid groundwork for later T cell receptor (TCR) and chimeric antigen receptor (CAR) therapeutic strategies now deployed clinically.

London – September 20, 2026 -- Business Worldwide Magazine has named MyPureSkin S.A, a Swiss nutricosmetics company, to its list of the 20 Most Innovative Healthcare Companies to Watch in 2026.

Swiss firm builds clinically validated skin-health platform from Health Valley base

Founded by Edgar Brandt and Tatiana Brandt in Switzerland's Health Valley, MyPureSkin operates on the premise that skin should receive the same nutritional and scientific attention as other organs. The company now sells across Europe, North America, the Middle East, and Australia.

Proprietary Nutrigevity framework anchors product development

MyPureSkin's formulations are built around NutrigevityTM, a proprietary framework targeting three biological pillars: Structure, Signalling, and Regeneration. The framework draws on expertise from clinical medicine, plastic surgery, gynaecology, micronutrition, and skin biology.

New Delhi – September 20, 2026 -- Apollo Athenaa Women's Cancer Centre has treated more than 30,000 women from over 110 cities and performed 1,000-plus cancer surgeries in its first year of operation, marking its anniversary as Asia's first dedicated cancer centre for women.

Centre completes 4,000+ chemotherapy cycles and 100+ reconstruction procedures in year one

Apollo Athenaa's clinical volumes in its debut year include over 4,000 chemotherapy cycles, more than 100 plastic and breast reconstruction procedures, and 120-plus VABB (vacuum-assisted breast biopsy) procedures. The centre built an integrated care model spanning breast and gynaecological oncology, reconstruction, medical and precision oncology, diagnostics and rehabilitation.

Provo, Utah – September 20, 2026 -- Canary Speech has been named to TIME and Statista's World's Top HealthTech Companies 2026 ranking, marking the second consecutive year the vocal biomarker technology firm has received the distinction.

TIME and Statista select 500 companies from thousands of HealthTech firms reviewed globally

The ranking evaluated companies across three primary data sources: Financial Performance Metrics, Reputation Analysis, and Online Engagement. The list was announced on September 20, 2026, and published on Time.com.

Oxford – September 19, 2026 -- Brainomix, an Oxford-based AI-powered medical imaging company, has been selected to join Future Fifty, the UK's invitation-only scale-up programme run by Tech Nation and Founders Forum Group.

Brainomix joins 24 other companies in a cohort that has raised £1.47 billion collectively

The latest Future Fifty cohort spans 10 sectors including AI, healthtech, biotech, fintech, energy and advanced manufacturing, and employs more than 3,800 people across the group. The programme has previously supported 30% of all UK tech unicorns and 40% of the country's decacorns, including Revolut and Wise.